| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
JP Morgan analyst Lisa Gill maintains GoodRx Holdings (NASDAQ:GDRX) with a Overweight and lowers the price target from $6 to...
TD Cowen analyst Charles Rhyee maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and lowers the price target from $7 to $6.
https://x.com/JenniferJJacobs/status/1986518429478568383
UBS analyst Kevin Caliendo maintains GoodRx Holdings (NASDAQ:GDRX) with a Neutral and lowers the price target from $4.25 to $4.
GoodRx Holdings (NASDAQ:GDRX) FY2025 Revenue expected to be more than $792.300M vs $797.952M Est
GoodRx Holdings (NASDAQ:GDRX) reported quarterly earnings of $0.08 per share which missed the analyst consensus estimate of $0....
Billionaire entrepreneur Mark Cuban offered rare praise for the Trump administration's push to lower prescription drug cost...
The all-in-one solution includes a virtual consultation, clinically proven prescription medication, and discreet home delivery,...
